ClinicalTrials.gg
CompletedNCT00337727Updated Jun 2, 2017Results posted

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

A Phase 3 interventional study of aprepitant and Comparator: ondansetron in Chemotherapy-Induced Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
848
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.

Enrollment
2nd of 61
848 · median 92
Started
2007
with 2 others
Phase 3
15 of 61
1 open now
Registered
6th of 61
by date
Lead sponsor
9 of 61
Merck Sharp & Dohme LLC

Among the 61 studies testing aprepitant in Vomiting, this one is the 2nd largest by enrollment, is one of 3 that started in 2007, is one of 15 in phase 3, and was the 6th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing aprepitant in Vomiting, or all of them as a file.
02

Study summary

The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC). Patients receiving more then one cycle of chemotherapy may opt to participate in an optional second cycle during which the patient will receive the same antiemetic regimen as cycle 1, except that an IV formulation of aprepitant will be given in place of the oral formulation on study day one. Study drug administration on subsequent days will be given orally as in cycle 1.

03

Conditions studied

  • Chemotherapy-Induced Nausea and Vomiting

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients will be naive to emetogenic chemotherapy with or cytologically confirmed malignant disease scheduled to receive a single dose of moderately emetogenic chemotherapy on study day 1
  • score of 60 or greater

Exclusion criteria

Exclusion Criteria:

  • Patient is scheduled to receive any dose of cisplatin
  • Patient will receive abdominal or pelvic radiation a week prior and up to 6 days after initiation of chemotherapy
  • Any allergies to study drug or antiemetics
  • Taking substrates/prohibited medication
  • Significant medical or mental conditions
  • Abnormal laboratory values (, absolute neutrophils, , ALT, or creatinine).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
848 participants (actual)

Study arms

  • Other
    1

    Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.

    Drug: aprepitant · Drug: Comparator: ondansetron · Drug: Comparator: dexamethasone · Drug: Comparator; Placebo (unspecified)

  • Other
    2

    Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.

    Drug: Comparator: ondansetron · Drug: Comparator: dexamethasone · Drug: Comparator: fosaprepitant dimeglumine · Drug: Comparator; Placebo (unspecified)

Interventions

  • aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.

    Also known as: MK0869

  • Ondansetron 8 mg capsule Three day treatment period.

    Also known as: Zofran®

  • dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.

    Also known as: DEXAMETHASONE TABLETS USP

  • fosaprepitant dimeglumine 115 mg

    Also known as: EMEND®

  • DrugComparator; Placebo (unspecified)

    dexamethasone 12mg Pbo tablets.

  • DrugComparator; Placebo (unspecified)

    Aprepitant 80 mg \& 125 mg Pbo capsules.

06

What researchers measure

Primary outcomes

  1. Number of Patients Who Reported No Vomiting

    The number of patients who reported No Vomiting in the overall phase in Cycle 1

    Time frame: Overall phase (0-120 hours post initiation of MEC) in Cycle 1.

Secondary outcomes

  1. Number of Patients Who Reported Complete Response

    The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1.

    Time frame: Overall phase (0-120 hours post initiation of MEC) in Cycle 1

07

Results

Posted Nov 6, 2009

Participant flow

This study was conducted at 58 investigative sites worldwide. The first patient entered the study on 16-Jan- 2007 and the last patient's last visit was on 28-Oct-2008.

Participant flow — Overall Study
MilestoneAprepitant RegimenStandard Regimen
Started430418
Completed412406
Not completed1812
Withdrew: Adverse event53
Withdrew: Lost to follow-up54
Withdrew: Physician decision10
Withdrew: Protocol violation40
Withdrew: Withdrawal by subject35

Outcome measures

PrimaryNumber of Patients Who Reported No Vomiting

The number of patients who reported No Vomiting in the overall phase in Cycle 1

Time frame:
Overall phase (0-120 hours post initiation of MEC) in Cycle 1.
Reported as:
Number · Participants
Number of Patients Who Reported No Vomiting
ParticipantsAprepitant RegimenStandard Regimen
Number of Patients Who Reported No Vomiting324252
Statistical analysis
  • Aprepitant Regimen vs Standard Regimen · Regression, Logistic · p = <0.01 (Superiority based on 2-sided level of significance of 0.05, based on a logistic regression model that included terms for treatment group, region and gender.)
SecondaryNumber of Patients Who Reported Complete Response

The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1.

Time frame:
Overall phase (0-120 hours post initiation of MEC) in Cycle 1
Reported as:
Number · Participants
Number of Patients Who Reported Complete Response
ParticipantsAprepitant RegimenStandard Regimen
Number of Patients Who Reported Complete Response292229
Statistical analysis
  • Aprepitant Regimen vs Standard Regimen · Regression, Logistic · p = <0.01 (Superiority based on 2-sided level of significance of 0.05, based on a logistic regression model that included terms for treatment group, region and gender.)

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aprepitant Regimen—12/430 (2.8%)265/430 (61.6%)
Standard Regimen—20/418 (4.8%)270/418 (64.6%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventAprepitant RegimenStandard Regimen
Febrile NeutropeniaBlood and lymphatic system disorders4/4303/418
CellulitisInfections and infestations2/4301/418
NeutropeniaBlood and lymphatic system disorders1/4301/418
Abdominal PainGastrointestinal disorders0/4301/418
ConstipationGastrointestinal disorders0/4301/418
IleitisGastrointestinal disorders0/4301/418
General physical health deteriorationGeneral disorders0/4301/418
PyrexiaGeneral disorders0/4301/418
Abdominal InfectionInfections and infestations0/4301/418
Herpes ZosterInfections and infestations0/4301/418
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAprepitant RegimenStandard Regimen
ConstipationGastrointestinal disorders37/43053/418
HeadacheNervous system disorders42/43049/418
DiarrhoeaGastrointestinal disorders40/43046/418
FatigueGeneral disorders47/43041/418
AnorexiaMetabolism and nutrition disorders35/43037/418
AlopeciaSkin and subcutaneous tissue disorders28/43032/418
AstheniaGeneral disorders26/43023/418
NauseaGastrointestinal disorders18/43011/418
Abdominal PainGastrointestinal disorders17/43016/418
DyspepsiaGastrointestinal disorders14/43013/418

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aprepitant RegimenStandard RegimenTotal
Mean57.1 ± 11.855.9 ± 12.656.5 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Aprepitant RegimenStandard RegimenTotal
Female327325652
Male10393196
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Aprepitant RegimenStandard RegimenTotal
Caucasian287296583
Asian493584
Black262046
Multi-racial5053103
Other181432
History of Motion Sickness
History of Motion Sickness(Participants)Aprepitant RegimenStandard RegimenTotal
Yes244165
No405376781
No Data - Assessment Not Completed112
History of Vomiting with Pregnancy
History of Vomiting with Pregnancy(Participants)Aprepitant RegimenStandard RegimenTotal
Yes6175136
No266250516
Not Applicable- Male Patients10393196
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010 Apr;18(4):423-31. doi: 10.1007/s00520-009-0680-9. Epub 2009 Jul 1. PubMed 19568773 ↗
  • Rapoport BL. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. Curr Med Res Opin. 2014 Sep;30(9):1875-81. doi: 10.1185/03007995.2014.925866. Epub 2014 Jun 12. PubMed 24911369 ↗
  • Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev. 2013 Feb;39(1):113-7. doi: 10.1016/j.ctrv.2012.09.002. Epub 2012 Oct 11. PubMed 23062719 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2007 to primary completion in Oct 2008, 21 months.

Results were first posted in Nov 2009, 1 year after primary completion.

Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2006
First posted
Jun 16, 2006
StartActual
Jan 1, 2007
Primary completionActual
Oct 28, 2008
CompletionActual
Nov 19, 2008
Results first posted
Nov 6, 2009
Last update
Jun 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00337727
Responsible party
Sponsor
First posted
Jun 16, 2006
Start date
Jan 1, 2007
Primary completion
Oct 28, 2008
Completion
Nov 19, 2008
Results posted
Nov 6, 2009
Last update
Jun 2, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aprepitant · Fosaprepitant

Start the discussion